PROK director granted 135,000 stock options

PROKIDNEY CORP. director Alan Lotvin received a grant of stock options as part of non-employee director compensation.

Rhea-AI Filing Summary

PROKIDNEY CORP. director Alan Lotvin received a grant of stock options as part of non-employee director compensation. The award covers 135,000 options to buy Class A Common Stock at an exercise price of $1.81 per share, all held directly.

The options vest in full on the earlier of the one-year anniversary of the grant date or the company’s next annual general shareholder meeting and expire on May 28, 2036. Following this grant, Lotvin holds 135,000 director stock options linked to the company’s Class A Common Stock.

Insider Trade Summary

Grant/Award: 135,000 shares

Grant/Award 1 txn

Insider Lotvin Alan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director stock option (right to buy)	135,000	$0.00	$0.00

Holdings After Transaction: Director stock option (right to buy) — 135,000 contracts (Direct)

Footnotes (2)

1. F1. These options were granted under the Issuer's non-employee director compensation policy.
2. F2. The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

Key Figures

Options granted: 135,000 options Exercise price: $1.81 per share Expiration date: May 28, 2036 +2 more

5 metrics

Options granted 135,000 options Director stock option grant to Alan Lotvin

Exercise price $1.81 per share Conversion or exercise price for director options

Expiration date May 28, 2036 Option term end for director grant

Underlying shares 135,000 shares Class A Common Stock underlying the options

Post-grant derivative holdings 135,000 options Total director options following transaction

Key Terms

Director stock option, non-employee director compensation policy, Class A Common Stock, exercise price, +1 more

5 terms

Director stock option financial

"Director stock option (right to buy)"

non-employee director compensation policy financial

"These options were granted under the Issuer's non-employee director compensation policy."

Class A Common Stock financial

"underlying_security_title": "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

exercise price financial

"conversion_or_exercise_price": "1.8100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PROK director Alan Lotvin report on this Form 4 for PROK?

Alan Lotvin reported receiving a grant of 135,000 director stock options. These options allow him to buy Class A Common Stock at $1.81 per share as part of PROKIDNEY CORP.’s non-employee director compensation policy.

What is the size and exercise price of Alan Lotvin’s new PROK options?

The grant covers 135,000 director stock options with an exercise price of $1.81 per share. Each option relates to one share of PROKIDNEY CORP. Class A Common Stock, providing potential future equity exposure if exercised.

When do Alan Lotvin’s PROK director stock options vest?

These options vest in full on the sooner of one year after the grant date or PROKIDNEY CORP.’s next annual general shareholder meeting. This single vesting date structure is typical for non-employee director compensation programs.

When do the PROK director stock options granted to Alan Lotvin expire?

The options expire on May 28, 2036, giving a long exercise window. After this expiration date, any unexercised options will lapse, so potential value depends on the stock price before that time.

Are Alan Lotvin’s PROK options a market purchase or compensation grant?

This is a compensation-related grant, not an open-market purchase. The Form 4 notes the options were granted under PROKIDNEY CORP.’s non-employee director compensation policy at a $1.81 exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/29/2026 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lotvin Alan

(Last) (First) (Middle)

C/O PROKIDNEY CORP

2000 FRONTIS PLAZA BLVD, SUITE 250

(Street)

WINSTON SALEM NORTH CAROLINA 27103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PROKIDNEY CORP. [ PROK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director stock option (right to buy)	$1.81	05/28/2026		A		135,000(1)		(2)	05/28/2036	Class A Common Stock	135,000	$0	135,000	D

Explanation of Responses:

1. These options were granted under the Issuer's non-employee director compensation policy.

2. The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

	/s/ Todd Girolamo, attorney in fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)